
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Nutrient Rich Natural products: Lift Your Wellbeing - 2
The Fate of Mechanical technology: 5 Headways Forming Tomorrow - 3
Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency - 4
Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024 - 5
Middle East hotels hit pandemic-era lows amid Iran war
What Yogurt Types Do You Know
Council removes proposal to rename park named after former president of Israel
Experience Is standing by: History's Most noteworthy Travelers
EU chief urges Iran to free imprisoned protesters, lift internet ban
Former 'Bachelorette' welcomes 1st baby via emergency c-section
Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
Step by step instructions to Think about Disc Rates Across Various Banks
'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
Which salad do you believe is a definitive group pleaser? Vote!












